Rosiglitazone and cardiovascular disease-recent controversy.
Pais
Prem
P
Clinical Trials Division, St. John's Medical College, Bangalore, India. prempais@ipchr.res.in
D003324:Coronary Artery Disease / Q000188:drug therapy / Q000401:mortality*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D009203:Myocardial Infarction / Q000401:mortality*; D017202:Myocardial Ischemia / Q000188:drug therapy / Q000401:mortality; D012307:Risk Factors; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000009:adverse effects*
D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone